Novartis CEO: No on megadeals, yes on medium-sized buyouts

Novartis ($NVS) CEO Joe Jimenez isn't reluctant to rule out megadeals in positioning the giant pharma for the future. But the right kind of "medium-sized" deals, all the rage these days in the biopharma industry, would be fine. The acquisition strategy, though, will have to be tailored to continue the company's dividend support plan. Story